Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.

[1]  Ling Liu,et al.  Construction of the Pharmacophore Model of Glycogen Synthase Kinase‐3 Inhibitors , 2007 .

[2]  S. Vadivelan,et al.  Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors , 2007, J. Chem. Inf. Model..

[3]  A. Valentini,et al.  Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells , 2007, Cancer biology & therapy.

[4]  H. Groen,et al.  Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. , 2006, Lung cancer.

[5]  P. Fischer,et al.  Protein structures in virtual screening: a case study with CDK2. , 2006, Journal of medicinal chemistry.

[6]  I. Chessell,et al.  Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[7]  Alex M Aronov,et al.  Toward a pharmacophore for kinase frequent hitters. , 2004, Journal of medicinal chemistry.

[8]  Stephen Green,et al.  Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. , 2003, Bioorganic & medicinal chemistry letters.

[9]  P. Mischnick,et al.  Determination of the DS and substituent distribution of cationic alkyl polyglycosides and cationic starch ethers by GLC after dealkylation with morpholine. , 2003, Carbohydrate Research.

[10]  L. Pearl,et al.  Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex , 2003, The EMBO journal.

[11]  L. Johnson,et al.  Structure-based design of cyclin-dependent kinase inhibitors. , 2002, Pharmacology & therapeutics.

[12]  H. Hibshoosh,et al.  Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. , 1999, Human pathology.

[13]  Y. Hosokawa,et al.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele‐specific expression , 1998, Genes, chromosomes & cancer.

[14]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[15]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[16]  P. Suzdak,et al.  Pyrazolo[1,5-a]pyridines and pyrazolo[1,5-b]pyridazines as 5ht3-antagonists , 1994 .

[17]  J. Marcus,et al.  RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines 1 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A. Arnold,et al.  Cyclin D and oncogenesis. , 1993, Current opinion in genetics & development.

[19]  R. Figlin,et al.  Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.

[20]  G. J. Bennett,et al.  Rearrangement of 1,3,5,8-tetraoxygenated xanthones in hot aqueous morpholine , 1989 .